SAGITTARIUS LIFE SCIENCE CORP |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.15 TWD | +0.37% |
|
-1.20% | -21.17% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,514 | 1,698 | 1,113 | 895 | 1,325 | 1,699 |
| Enterprise Value (EV) 1 | 866 | 1,208 | 756.5 | 564.1 | 1,066 | 1,497 |
| P/E ratio | -16.5 x | -14.2 x | -15.1 x | -10.4 x | -17.9 x | -30.9 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.68 x | 3.87 x | 1.99 x | 1.52 x | 2.5 x | 3.86 x |
| EV / Revenue | 2.1 x | 2.75 x | 1.36 x | 0.96 x | 2.02 x | 3.4 x |
| EV / EBITDA | -8.43 x | -13.4 x | -12.3 x | -6.9 x | -14.2 x | -25.9 x |
| EV / FCF | -21.3 x | -18.6 x | -13.8 x | -36.4 x | -21.2 x | -53.1 x |
| FCF Yield | -4.69% | -5.39% | -7.23% | -2.75% | -4.72% | -1.88% |
| Price to Book | 1.9 x | 2.52 x | 1.9 x | 1.73 x | 3 x | 3.3 x |
| Nbr of stocks (in thousands) | 32,773 | 32,773 | 32,546 | 32,546 | 32,546 | 32,546 |
| Reference price 2 | 46.20 | 51.80 | 34.20 | 27.50 | 40.70 | 52.20 |
| Announcement Date | 4/1/19 | 3/31/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/21/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 411.4 | 438.7 | 558.2 | 587.6 | 529.1 | 440.5 |
| EBITDA 1 | -102.7 | -90.02 | -61.61 | -81.73 | -74.85 | -57.68 |
| EBIT 1 | -114.6 | -105.1 | -71.8 | -90.01 | -82.23 | -64.38 |
| Operating Margin | -27.86% | -23.96% | -12.86% | -15.32% | -15.54% | -14.62% |
| Earnings before Tax (EBT) 1 | -91.81 | -110.3 | -74 | -87.46 | -76.5 | -56.82 |
| Net income 1 | -91.81 | -119.5 | -74.12 | -86.42 | -74.2 | -55.04 |
| Net margin | -22.32% | -27.24% | -13.28% | -14.71% | -14.02% | -12.5% |
| EPS 2 | -2.802 | -3.647 | -2.272 | -2.655 | -2.280 | -1.691 |
| Free Cash Flow 1 | -40.62 | -65.08 | -54.72 | -15.51 | -50.35 | -28.2 |
| FCF margin | -9.87% | -14.83% | -9.8% | -2.64% | -9.52% | -6.4% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/1/19 | 3/31/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/21/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 648 | 490 | 357 | 331 | 258 | 202 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -40.6 | -65.1 | -54.7 | -15.5 | -50.3 | -28.2 |
| ROE (net income / shareholders' equity) | -10.4% | -16.3% | -11.8% | -15.6% | -15.5% | -11.6% |
| ROA (Net income/ Total Assets) | -7.32% | -7.7% | -5.78% | -7.94% | -8.19% | -6.47% |
| Assets 1 | 1,254 | 1,551 | 1,282 | 1,088 | 905.9 | 850.8 |
| Book Value Per Share 2 | 24.30 | 20.60 | 18.00 | 15.90 | 13.60 | 15.80 |
| Cash Flow per Share 2 | 19.80 | 15.90 | 12.10 | 7.860 | 5.820 | 4.110 |
| Capex 1 | 0.1 | 14.7 | 10.9 | 8.22 | 1.09 | 2.01 |
| Capex / Sales | 0.02% | 3.35% | 1.95% | 1.4% | 0.21% | 0.46% |
| Announcement Date | 4/1/19 | 3/31/20 | 3/31/21 | 3/31/22 | 3/31/23 | 3/21/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -21.17% | 41.52M | |
| +17.39% | 8.62B | |
| +6.26% | 7.68B | |
| +7.55% | 6.38B | |
| -7.57% | 3.74B | |
| -5.30% | 3.71B | |
| -1.78% | 1.34B | |
| -27.39% | 1.12B | |
| +18.29% | 1.05B | |
| -9.48% | 913M |
- Stock Market
- Equities
- 3205 Stock
- Financials Sagittarius Life Science Corp